Skip directly to content

TB/HIV Project News





Resource Tracking

Community Engagement



Zero Campaign


2014 Pipeline Report
July 20, 2014 – HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.
Read the TB chapters online:

An Activist's Guide to Tuberculosis Drugs

May 29, 2014 - TB treatment must be shorter, simpler, less toxic, and more tolerable and affordable. Activists can contribute to the development and uptake of improved TB treatment by calling attention to research, quality of medications, and access priorities. This guide provides a brief summary of safety and efficacy data for those drugs currently in use for TB (many of which have been approved for other diseases but are used off-label for TB), and suggests advocacy points for activists.

Falling Funding for Tuberculosis Research Threatens to Derail TB Elimination Efforts in the United States
Research Dollars Drop Just as Old Disease Grows More Difficult to Treat

March 24, 2014, Washington, D.C. – The goal of eliminating tuberculosis (TB) as a public health threat in the United States is under threat, a new policy brief released today by Treatment Action Group (TAG) shows. Analysis conducted by TAG reveals that spending on TB research and development (R&D) among U.S. government agencies declined from 2009 to 2012 in the face of budget instability, sequestration, and the rising costs of biomedical research.

Flatlined: U.S. Government Investments in Tuberculosis Research and Development, 2009–2012
March 2014 – The goal of eliminating tuberculosis (TB) as a public health threat in the United States is under threat. In 1989, the U.S. government committed to ending the TB epidemic through the formation of a national TB elimination plan. Since then, the heart of the U.S. strategy for domestic TB elimination has progressed through a combination of visionary research linked to bold implementation. As a result of this two-pronged strategy, there were only 9,951 new domestic cases of TB in 2012, the lowest level since reporting began in 1953. Yet falling funding for TB research threatens to roll back the hard-won achievements of the last two decades.

CRAG, TAG Welcome Sanofi U.S. Commitment to Reduce the Price of Tuberculosis Drug Rifapentine
December 12, 2013 – The Community Research Advisors Group (CRAG) and Treatment Action Group (TAG) welcome the Sanofi U.S. decision to lower the price of the tuberculosis (TB) drug rifapentine to $32 per 32-tablet blister pack. The company indicates that the new price will become effective in January 2014 under 340(b) Public Health Service pricing.

Treatment Action Group Applauds European Approval of New Drug to Fight Tuberculosis, Demands Expanded Access and Affordable Pricing
November 22, 2013 — Approval of and access to delamanid are crucial while further research is pending
NEW YORK, NY, USA – Treatment Action Group (TAG) congratulates the Committee for Medicinal Products for Human Use (CHMP) for its recommendation to the European Medicines Agency (EMA) to grant marketing approval to delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) now in phase III clinical trials. MDR-TB treatment options that do not include new drugs are long, toxic, difficult to tolerate, and often ineffective.

October 30, 2013 – Activists stormed the stage at the World Health Organization (WHO) sponsored Stop TB Symposium during the 44th Union World Conference on Lung Health. TAG's TB Project Director Colleen Daniels called for global action and a new global attitude in the fight against TB.

Tuberculosis: Behind the Numbers Video Series

  • A Double Blow: Private-Sector Funding for TB Research Drops Sharply Amid Severe Public-Sector Budget Cuts
    As Threat of Drug-Resistance Grows, Big Pharma Decreases Investments in TB research by 22 Percent
    October 29, 2013 – Paris, France – The 2013 Report on Tuberculosis Research Funding Trends, 2005–2012 finds that funding for tuberculosis research and development (TB R&D) dropped by US$30.4 million compared with 2011—the first time funding has fallen since TAG began tracking investments in 2005. Funding declined for diagnostic, drug, vaccine, and operational research, increasing the likelihood that new tools to fight TB will remain out of reach for the 8.7 million people who develop TB each year.
  • October 2013 – Mark Harrington, executive director of TAG, was featured in an online panel discussion about the global crisis of drug-resistant tuberculosis (DR-TB). The webcast, New Approaches to Drug-Resistant Tuberculosis, was hosted by Doctors Without Borders/Médecins Sans Frontières (MSF) and New York Times science writer Denise Grady. The panel comprised health care workers and patient advocates working to improve treatment for people living with DR-TB, including Dr. Grania Brigden, TB advisor, MSF Access Campaign; Cathy Hewison, TB medical advisor at MSF; Mark Harrington, executive director of Treatment Action Group; and Evaline Kibuchi, senior TB advocacy manager at the Kenya AIDS NGO Consortium (KANCO).
  • Cascades: Improving TB Care
    Please join Treatment Action Group, Partners In Health, Médecins Sans Frontières, the Stop TB Partnership and the Department of Global Health and Social Medicine at Harvard Medical School for a satellite symposium at the 44th Union World Conference on Lung Health.

    Friday, November 1, 2013
    18h00 – 21h00
    Hyatt Regency Paris Etoile
    3, Place du Général Koenig
    Batignolles/ Longchamp Room
  • First-Ever Targeted Roadmap Outlines Steps to End Childhood TB Deaths
    Cost to end deaths from childhood TB estimated to be at least US$120 million annually
    WASHINGTON D.C. | October 1, 2013 -- The deaths of more than 74 000 children from tuberculosis (TB) could be prevented each year through measures outlined in the first ever action plan developed specifically on TB and children.
    The World Health Organization, the International Union Against Tuberculosis and Lung Disease, the Stop TB Partnership and other partners will launch a roadmap outlining the path towards zero deaths from childhood tuberculosis.

    Tuesday, 1 October 2013
    11:00 a.m. Press Conference
    2:00 p.m. Workshop
    PATH, 455 Massachusetts Ave, NW, Suite 1000
    Washington, DC 20001    

    Please join us for the launch.

  • Treatment Action Group Criticizes European Refusal of New Drug to Fight Tuberculosis
     — Approval of and access to delamanid is crucial while further research is pending —
    July 29, 2013 – Treatment Action Group (TAG) is disappointed by the failure of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to recommend marketing approval for delamanid, a new drug in development for multidrug-resistant tuberculosis (MDR-TB).